As per reports, Jubilant Life Sciences officials claimed that they recently made an important deal with the industrialized US pharmaceutical firm.

Giving some more details about the signed bond, the officials affirmed that the deal would certainly be aimed at manufacturing an OTC product in women physical condition and individual care segment.

However, the officials were forced to take this innovative step after the nation's health data revealed that just because of proper health care product delivery, majority of the women suffered from fatal health complications.

Meanwhile, the reports further stated that the conformity was signed with the company's Chief division officer, Jubilant HollisterStier, and the manufactured goods would be soon launched at its Montreal facility care center based in Canada.

In an official statement, the Company officials further wrote, the planned step is a seize or disburse agreement with a smallest amount of promises and has a sum worth of over $70 million for a period of over 4 years with a likelihood of further extension of 2 years against a higher amount of business proceedings.

Speaking on the issue, Hari S Bhartia, the Company Chairman and Managing Director, said, "This contract is an outcome of our strategy to expand our offerings across products and geographies".